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Abstract
AIM: Portal hypertension is a common complication of 
liver cirrhosis and significantly increases mortality and 
morbidity. Previous reports have suggested that the 
compound thalidomide attenuates portal hypertension 
(PHT). However, the mechanism for this action is not 
fully elucidated. One hypothesis is that thalidomide 
destabilizes tumor necrosis factor α (TNFα) mRNA and 
therefore diminishes TNFα induction of nitric oxide 
synthase (NOS) and the production of nitric oxide (NO). 
To examine this hypothesis, we utilized the murine partial 
portal vein ligation (PVL) PHT model in combination with 
endothelial or inducible NOS isoform gene knockout mice. 
METHODS: Wild type, inducible nitric oxide synthase 
(iNOS)-/- and endothelial nitric oxide synthase (eNOS)-/- 
mice received either PVL or sham surgery and were 
given either thalidomide or vehicle. Serum nitrate 
(total nitrate, NOx) was measured daily for 7 d as a 
surrogate of NO synthesis. Serum TNFα level was 
quantified by enzyme-linked immunosorbent assay. 
TNFα mRNA was quantified in liver and aorta tissue by 
reverse transcription-polymerase chain reaction. PHT 
was determined by recording splenic pulp pressure 
(SPP) and abdominal aortic flow after 0-7 d. Response 
to thalidomide was determined by measurement of 
SPP and mean arterial pressure (MAP). 
RESULTS: SPP, abdominal aortic flow (Qao) and 
plasma NOx were increased in wild type and iNOS-/- 
PVL mice when compared to sham operated control 
mice. In contrast, SPP, Qao and plasma NOx were not 
increased in eNOS-/- PVL mice when compared to sham 
controls. Serum TNFα level in both sham and PVL mice 
was below the detection limit of the commercial ELISA 
used. Therefore, the effect of thalidomide on serum 
TNFα levels was undetermined in wild type, eNOS-/- 
or iNOS-/- mice. Thalidomide acutely increased plasma 
NOx in wild type and eNOS-/- mice but not iNOS-/- 
mice. Moreover, thalidomide temporarily (0-90 min) 
decreased mean arterial pressure, SPP and Qao in wild 
type, eNOS-/- and iNOS-/- PVL mice, after which time 
levels returned to the respective baseline.
CONCLUSION: Thalidomide does not reduce portal 
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pressure in the murine PVL model by modulation of 
NO biosynthesis. Rather, thalidomide reduces PHT by 
decreasing MAP by an undetermined mechanism.
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Core tip: The research innovation detailed in this manu-
script is the use of nitric oxide synthase (NOS) isoform 
specific gene deleted mice to better understand 
the underlying mechanisms for the development 
of portal hypertension (PHT). PHT is a significant 
complication of liver disease and increases morbidity 
and mortality. Our study examined the hypothesis 
that the compound thalidomide reduces PHT by 
decreasing the biosynthesis of nitric oxide (NO) via  
destabilizing tumor necrosis factor alpha mRNA levels. 
We demonstrate that thalidomide induces NO via  
increased inducible nitric oxide synthase isoform of 
NOS; however, thalidomide reduction in PHT was NOS 
isoform independent.
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INTRODUCTION
Portal hypertension (PHT) is a complication typically 
associated with underlying liver disease whereby 
portal pressure exceeds 10 mmHg[1]. In general, PHT 
is predominantly a sequela of alcoholic, non-alcoholic 
steatohepatitis or viral cirrhosis[2] and is augmented 
by the formation of a systemic hyper-dynamic circu-
lation manifesting as a generalized reduced vascular 
resistance, via vasodilation, promoting systemic and 
mesenteric hyperemia[3,4]. Increased hepatic resistance 
in combination with hyperemia promotes redirection 
of portal venous flow from the liver towards, inter alia, 
mesenteric and azygous venous beds to form esophageal 
and ectopic varices[5]. Generally, esophagogastric varices 
have the greatest capacity for hemorrhage amongst 
varices and in combination with liver failure significantly 
increase mortality and morbidity[6]. 
Previous studies have detailed the importance of 
nitric oxide synthase (NOS) enzymes in the development 
of PHT. In particular, the NOS isoform endothelial NOS 
(eNOS) is thought to be important to PHT by regulating 
biosynthesis of the potent vasodilator nitric oxide 
(NO)[7-9]. Decreased hepatic eNOS results in hepatic 
sinusoid constriction and increased hepatic resistance 
to portal venous flow[10]. In contrast, increased extra-
hepatic vascular eNOS promotes vasodilation and the 
development of hyper-dynamic circulation by increasing 
blood flow to the liver[11,12]. Moreover, functional eNOS is 
also found in circulating micro-particles (< 1 μm) shed 
from endothelial and blood cells. Studies show that 
micro-particles are increased in patients with endothelial 
dysfunction but eNOS expression is decreased[13]. 
Consequently, the precise mechanism/role for eNOS in 
PHT is not clear. We do know that eNOS activation is 
multifaceted and includes protein kinase B AKT, GTPase-
activating protein, sarcoma proto-oncogene and G 
protein-coupled receptor-2 kinase activity culminating 
with eNOS phosphorylation and translocation to the cell 
membrane[8,14-16]. 
In addition, the cytokine tumor necrosis factor-
alpha (TNF-α) is thought to be important in the 
pathogenesis of PHT by increasing eNOS activity and 
NO production[17,18]. Therefore, inhibition of TNFα 
has the potential to ameliorate portal pressure and 
reduce mortality and morbidity associated with PHT. 
Previous studies have shown that the compound 
thalidomide destabilizes TNFα mRNA[19] and prevents 
the development of PHT in portal vein ligated (PVL) 
animals[20,21]. However, the precise mechanism by which 
thalidomide abrogates PHT is not fully understood. 
In human studies, thalidomide reduces hepatic 
venous pressure gradient without reducing systemic 
hemodynamic parameters[22]. This suggests that: (1) 
TNFα is not associated with PHT associated hyper-
dynamic circulation; and (2) thalidomide reduces PHT 
independent of TNFα and NO. 
To examine the mechanistic connection between 
thalidomide, TNFα and NO on PHT, we utilized the 
murine, non-inflammatory, pre-hepatic PVL model of 
PHT and commercially available iNOS and eNOS gene 
knockout mice and examined changes to TNFα and 
PHT in response to thalidomide. We have previously 
shown that in the PVL model of PHT, eNOS is the 
dominant NOS isoform and in its absence PHT does 
not develop[9]. We anticipated that in PVL mice, TNFα 
would be increased and that thalidomide would 
reduce this increase and associated PHT but there 
would be no response to thalidomide in eNOS-/- mice. 
In contrast to this expectation, we found that TNFα 
levels were below detectable limits of the enzyme-
linked immunosorbent assay (ELISA) used and that 
thalidomide caused: (1) an iNOS dependent increase 
in circulating NOx levels; and (2) thalidomide reduction 
of portal pressure was NOS isoform independent and 
was commensurate with a NOS independent drop 
in systolic blood pressure. Because TNFα levels in 
mice were below detectable levels, we were unable 
to determine response to thalidomide administration. 
Liver and thoracic aorta tissue TNFα mRNA expression 
levels were detectable and levels were not significantly 
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changed in response to PVL surgery but were increased 
following thalidomide administration. This information 
demonstrates that thalidomide improves portal hemo-
dynamics independent of NO and is linked to a reduction 
in mean arterial blood pressure. 
MATERIALS AND METHODS
Unless otherwise stated, all chemicals were purchased 
from Sigma, MO. The partial portal vein ligation 
pre-hepatic PHT model was used. All studies were 
approved by the University of Rochester committee 
for animal research and adhered to AAALC and federal 
guidelines for the humane care and treatment of 
animals. Mice were maintained in sterilized isolette 
cages on a 12-h light/dark cycle and were allowed 
access to food and water ad libitum. Mice [C57B/6J, 
C57BL/6J-NOS2tm1Unc (iNOS-/-)[23] and C57BL/6J-
NOS3tm1Unc (eNOS-/-)[24] (Jackson Labs, MA)] were 
anesthetized using halothane inhalation. A midline 
laparotomy was performed and the portal vein was 
exposed. A blunt-ended 27-gauge needle was placed 
alongside the portal vein and a 4-0 silk suture was tied 
around the vein and needle, after which the needle 
was withdrawn, producing a standardized stenosis. In 
sham animals, the procedure consisted of dissection 
and visual inspection of the portal vein without ligature. 
The abdomen was closed and the animals were 
allowed to recover under a heat lamp. For thalidomide 
studies, (25-100 mg/kg per day) thalidomide (α-N-
phthalyllutamic-acid-imine) or dimethyl sulfoxide 
(DMSO) vehicle was given 16 h prior and 4 h following 
PVL or sham and every 24 h thereafter. 
Physiological measurements
Physiological measurements were performed as 
previously described[9]. At the indicated times post 
sham-operation or PVL, animals were anesthetized 
(halothane) and subjected to laparotomy to allow 
physiological measurements to be taken. Splenic 
pulp pressure (SPP) was measured as an index of 
portal venous pressure. To measure SPP, a cannula 
made from a 25-gauge needle connected to a saline-
filled manometer was inserted into the spleen pulp. 
Abdominal aortic flow was measured by placing an 
ultrasonic Doppler flow probe (Transonic #11RB) around 
the abdominal aorta between the diaphragm and celiac 
artery. Flow rates were obtained with a Transonic T206 
Blood Flow Meter (Transonic Instruments, Ithaca, NY). 
Aortic blood flows were standardized per gram of body 
weight.
Systolic blood pressure and heart rate were deter-
mined by non-invasive tail cuff plethysmography using 
the Visitech BP-2000 Blood Pressure Analysis system 
as per manufacturer’s instructions (Visitech systems, 
Apex, NC). Baseline values were obtained for 4 d to 
train the mice (n = 8) in the measurement of blood 
pressure and heart rate. On the fifth day, mice were 
given 50 mg/kg thalidomide and the blood pressure 
and heart rate was calculated for 10 min every 20 min.
Plasma TNFα and NOx levels
Blood was collected by cardiac puncture, injected 
into heparinized tubes and centrifuged. Plasma TNFα 
was measured by sandwich ELISA in accordance 
with manufacturer’s instructions (#MTA00B, RD 
systems, Minneapolis, MN). TNFα was measured 0, 1, 
3, 6, 12, 16, 20 and 24 h and 2, 3, 4, 5, 6 and 7 d 
following PVL operation. Plasma NOx was determined 
using the Griess reaction[25] using a commercially 
available kit (#NB98, Oxford Biomedical, Rochester 
Hills, MI).
In vitro cell culture: RAW264 mouse macrophage 
cells (#TIB-71 ATCC, Manassas, VI) were cultured in 
the presence or absence of LPA and/or 25-100 μg/mL 
thalidomide for 0-24 h. 
Gene expression: TNFα, eNOS and iNOS mRNA 
from liver, aorta or RAW264 cells were determined by 
reverse transcription-polymerase chain reaction (RT-PCR) 
using gene-specific primers (200 ng) and 1 μg cDNA: 
eNOS: 5’GTGTGAAGGCAACCATTCTG 3’ACTCATCCATG 
CACAGGACC, INOS: 5’GGCTTCACGGGTCAGAGCCA 
3’TGCCCATTGC TGGGACAGTC TNFα 5’CTGTAGCC­
CACGTCGTAGC 3’TTGAGATCCATGCCGTTG 3 (cycle = 1 
min each of 94 oc, 60 oc and 74 oc × 35). Primers were 
purchased from Life Technologies, Grand Island, NY.
Statistical analysis
The data shown are mean ± SE, with 3-7 animals 
per experimental group. Statistical significance was 
estimated using ANOVA statistical analysis (SPSS, IBM).
RESULTS
TNF-α and NOx levels following PVL or thalidomide 
administration: plasma TNFα and NOx levels were 
determined following sham or PVL ligation and after 
thalidomide injection. TNFα levels were below the 
detectable levels of the assay. Consequently, no 
increase was detected following PVL and no decrease 
following thalidomide injection. Injection of 1 mg/kg 
LPS increased serum TNFα from undetectable levels 
to 192 pg/mL. Plasma NOx was increased significantly 
following PVL in wild type mice, peaking at 2 d post 
PVL surgery (Figure 1A). This PVL induced NOx at 
2 d post-surgery was eNOS specific. NOx was not 
increased in eNOS-/- mice following PVL but was 
increased in iNOS-/- mice (Figure 1B). Thalidomide 
induction of NOx was iNOS specific. Serum NOx was 
not increased in iNOS-/- mice following thalidomide 
injection but was increased in eNOS-/- mice (Figure 
1C). Thalidomide increased iNOS mRNA levels in aorta 
and liver tissue samples (75% and 162% respectively 
at 100 mg/kg). No change in eNOS expression was 
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Table 1  Splenic pulp pressure and abdominal aortic flow 7 d 
post portal vein ligation or sham
observed. 
Hepatic and arterial TNFα, eNOS and iNOS 
expression following thalidomide administration: 
thalidomide is reported to destabilize TNFα mRNA[19]. 
In immortalized macrophage cells (RAW263.3), 
we found that thalidomide reduced TNFα mRNA in 
unstimulated and LPS stimulated cells (81.7% and 
78.6% respectively). In contrast, thalidomide did 
not reduce LPS stimulated iNOS mRNA induction. 
The effect of thalidomide in vivo was determined by 
quantification of hepatic and arterial tissue TNFα, 
eNOS and iNOS expression ± thalidomide by RT-
PCR. TNFα mRNA was increased by 62% in thoracic 
aorta tissues and 34% in the liver tissues. In a similar 
manner, hepatic iNOS was increased 70% and 49% 
respectively. No change in eNOS mRNA was observed.
Effects of thalidomide on mean blood pressure, 
heart rate and portal hemodynamics following PVL: 
in vehicle treated mice, splenic pulp pressure and 
abdominal aortic flow were increased significantly 
7 d following PVL (Table 1). Treatment of mice with 
50 mg/kg thalidomide resulted in a temporary (90 
min) reduction in elevated splenic pressure and mean 
systolic blood pressure (58% and 70% reduction 
respectively) (Figure 2A and B). Thalidomide induced 
reduction was maximal 30-60 min following injection 
and after which time splenic pulp pressure and mean 
arterial pressure recovered to an elevated level by 90 
min. No significant change in heart rate was observed 
following thalidomide administration in PVL or sham 
mouse groups. 
Role of NOS isoforms on thalidomide: to determine 
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Figure 1  Portal vein ligation and thalidomide increases nitric oxide via endothelial and inducible nitric oxide synthase respectively. Plasma total nitrate (NOx) 
was measured daily for 7 d in wild type (WT), endothelial nitric oxide synthase (eNOS)-/- and inducible nitric oxide synthase (iNOS)-/- mice following portal vein ligation 
(PVL) or sham surgery. A: Plasma NOx increased following PVL in wild type mice but not following sham surgery. Levels increased to a maximum 2 d after PVL, 
after which NOx returned to pre-surgical baseline; B: Plasma NOx increased 2 d following PVL in iNOS-/- but not eNOS mice. In eNOS-/- mice NO was not increased 
following PVL; C: Unadulterated 8 wk WT, eNOS-/- and iNOS-/- mice were given 50 mg/kg thalidomide or vehicle. Blood was collected by cardiac puncture and plasma 
was assayed for NOx. Plasma NOx was significantly increased by the administration of thalidomide in WT and eNOS-/- mice but was reduced in iNOS-/- mice. aP < 0.05 
vs other groups.
Splenic pulp pressure 
(cmH2O)
Abdominal aortic flow 
(mL/min per gram)
Wild type sham    6.9 ± 0.4 0.17 ± 0.02
Wild type 7 d PVL   25.4 ± 3.1a  0.27 ± 0.04a
eNOS-/- sham    6.9 ± 0.3 0.15 ± 0.01
eNOS-/- 7 d PVL       7 ± 0.5 0.15 ± 0.01
iNOS-/- 7 d sham 6.7 ± 1 0.16 ± 0.01
iNOS-/- 7 d PVL   21.1 ± 0.4c  0.23 ± 0.06c
aP < 0.05 vs wild type sham t-test; cP < 0.05 vs iNOS-/- 7d sham t-test; mean 
± SE (n = 4-7). iNOS: Inducible nitric oxide synthase.
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the role of NOS isoforms on the transient hemodynamic 
response to thalidomide, wild type, eNOS-/- and iNOS-/- 
7 d PVL mice were treated with 50 mg/kg thalidomide 
and hemodynamic measurements were performed 
30 min thereafter. Portal pressure and systolic blood 
pressure were significantly reduced in all mice groups 
(Figure 3). Reduction in hemodynamics in response to 
thalidomide was NOS isoform independent. 
TNFα aortic and hepatic expression post PVL: to 
evaluate the role of TNFα in the PVL model, levels 
were determined by RT-PCR in aorta and liver tissue 
samples 0-4 d following PVL. TNFα was generally 
unchanged in response to PVL in both liver and aorta 
samples. However, there was a transient reduction 
in TNFα expression 3 h post PVL within aortic tissues 
but this reduction was not significantly significant (P 
= 0.1) (Figure 4). Whole tissues were used and so 
differentiation between muscle, nervous, connective 
and epithelial tissue was not investigated.
DISCUSSION
In 1998, the US Food and Drug Administration approved 
the use of thalidomide for the treatment of leprosy 
and multiple myeloma. Additional research has investi-
gated the benefit of thalidomide in animal models of 
Alzheimer’s[26], pancreatitis[27], colitis[28] and PHT[20]. 
The purpose of this manuscript is not to advocate 
the use of thalidomide for the treatment of PHT. That 
claim is beyond the scope of our experimental studies 
and we leave that analysis for others. Using the PVL 
murine model of pre-hepatic PHT in eNOS-/- and INOS-/- 
deficient animals, this study investigates thalidomide 
abrogation of PHT via mediating activation of NO 
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Figure 2  Thalidomide temporarily ameliorates splenic pulp pressure and mean systolic blood pressure in 7 d portal vein ligation mice. A: 7 d wild type 
sham and portal vein ligation (PVL) mice were treated with 50 mg/kg thalidomide ip and splenic pulp pressure was measured 0-150 min following administration. 
Splenic pulp pressure was rapidly and temporarily decreased by thalidomide; after 2 h pressure returned back to pre-thalidomide levels; B: Systolic blood pressure 
was also measured in 7 d PVL wild type mice following the administration of 50 mg/kg thalidomide or vehicle control. In a similar manner to splenic pulp pressure the 
systolic blood pressure was temporarily decreased by thalidomide. aP < 0.05 vs control group.
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Figure 3  Thalidomide reduction of splenic pulp pressure and systolic blood pressure is endothelial and inducible nitric oxide synthase independent. 7 d 
portal vein ligation wild type, endothelial nitric oxide synthase (eNOS)-/- and inducible nitric oxide synthase (iNOS)-/- mice were treated with 50 mg/kg thalidomide or 
dimethyl sulfoxide vehicle control ip. Splenic pulp pressure (A) and systolic blood pressure (B) were measure 60 min after administration. Thalidomide reduced splenic 
pulp pressure and systolic pulp pressure in wild type, eNOS-/- and iNOS-/- mice (n = 4 mice per group, aP < 0.05 vs control group).
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production. Our data shows that thalidomide increases 
NO production, via induction of iNOS, but this increase 
is not important to thalidomide transient reduction 
of PHT. Moreover, given that TNFα expression in liver 
and aorta tissues was unchanged in response to PVL, 
the murine PVL model is not suitable to study the 
role of TNFα in PHT. However, the demonstration that 
thalidomide temporarily reduces mean systemic blood 
pressure by an NO independent mechanism illustrates 
that thalidomide may be beneficial to prevent variceal 
formation and hemorrhage, a common problem 
associated with PHT, especially in patients that are 
non-responsive to current β-blocker therapy to reduce 
systemic blood pressure[29]. 
The scientific consensus is that the vasodilator NO 
plays a major role in the development and sustained 
vasculopathy of PHT[4]. However, the mechanisms 
controlling NO biosynthesis in the context of PHT 
are not clearly defined. Previous investigations using 
animal models of PHT and human studies suggest a 
role for TNF-α in vasodilatation by promoting increased 
NO production[30] by arguing that TNF-α induction of 
NOS isoforms (eNOS, and/or iNOS) promotes the 
development of a hyper-dynamic circulation and 
vascular hypo-responsiveness to vasoconstrictors 
associated with this pathological dysfunction[31]. 
Therefore, inhibition of TNFα is a potential mechanism 
in which to reduce PHT. Previous studies have shown 
that the compound thalidomide reduces TNFα[8,32]. 
The purpose of this manuscript was to investigate the 
hypothesis that TNFα modulates PHT via nitric oxide 
synthase enzyme[33]. We found that thalidomide, 
rather than reduce NO levels, increased circulating 
plasma NOx levels via iNOS. Moreover, although 
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Figure 4  Portal vein ligation does not increase hepatic or aortic tumor necrosis factor alpha mRNA expression. Pre-hepatic portal hypertension was induced 
in wild type mice by partial ligation of the portal vein. 0-24 h post ligation livers (A) and thoracic aortas (B) were harvested and quantified for tumor necrosis factor 
(TNF) mRNA by reverse transcription-polymerase chain reaction. TNFα was not changed within livers and aorta following portal vein ligation (PVL). Figures are 
representative of three experiments. Hepatic (C) and aortic (D) TNFα expression was unchanged 0-4 d post PVL. Line graphs represent mean ± SE. n = 5 mice.
Liver TNFα mRNA post PVL
9000
6000
3000
0
Re
la
tiv
e 
m
R
N
A 
le
ve
l
90 min            3 h               2 d               4 d
Aorta TNFα mRNA post PVL
9000
6000
3000
0
Re
la
tiv
e 
m
R
N
A 
le
ve
l
90 min             3 h               2 d               4 d
C
Theodorakis NG et al . PHT and NOS isoforms
thalidomide does reduce TNFα mRNA levels in mouse 
macrophage cells (RAW286.3), thalidomide increased 
TNFα and iNOS mRNA expression in murine liver 
and thoracic aorta tissues, suggesting that in vivo 
thalidomide increases TNFα and iNOS levels. It is not 
unexpected that thalidomide would modulate TNFα 
and iNOS similarly as co-regulation of TNFα and iNOS 
in response to stimuli is well described[34,35], as is 
the interaction between TNFα expression and iNOS 
expression[36,37]. Moreover, TNFα neutralizing antibodies 
are known to reduce iNOS expression[38-40]. 
Despite detecting an increase in TNFα expression, we 
were unable to detect circulating TNFα in sham or PVL 
mice irrespective of thalidomide administration using a 
highly specific commercially available ELISA, arguing 
against a role for TNFα in PVL models of PHT. However, 
studies by others have detected TNFα in rodent models 
of PVL using biological cell based assays[20]. The fact 
that TNFα neutralizing antibodies reduce NO and portal 
pressure in PVL rats suggests that TNFα is important in 
the PVL model via modulation of NOS[30]. Although TNFα 
levels were undetectable, the effects of thalidomide 
on NOS isoforms can be determined by measuring 
circulating NO levels, hemodynamic changes and TNFα 
mRNA levels. 
In rat PHT models, thalidomide administration 
demonstrated a significant correlation between TNFα 
plasma levels and mean arterial pressure among PVL 
animals[20]. Thalidomide has been noted to have many 
possible vascular effects, including anti-angiogenesis[41], 
disruption of mRNA transcription causing attenuation of 
the nuclear factor kappa B mediated gene expression[42], 
increase of the production of free radicals to elicit oxidative 
stress[43] and directly through systemic circulatory and/
or direct cardiac effects[44]. Consequently, a therapeutic 
role for thalidomide in patients with cirrhosis has been 
proposed[22]. We found that thalidomide reduced PHT via 
a significant reduction in mean arterial pressure (MAP) 
that was NOS isoform independent and irrelevant to 
circulating NO levels. MAP is approximately determined 
from measurements of the systolic pressure and the 
diastolic pressure over a cardiac cycle and is determined 
by the cardiac output (CO), systemic vascular resistance 
(SVR) and central venous pressure [MAP = (CO - SVR) 
+ CVR]. Cardiac output is related to both heart rate and 
stroke volume (SV). Both thalidomide and TNFα have 
been linked to vascular regulation. 
Thalidomide has been shown to improve CO by 
increasing the left ventricular ejection fraction[44,45] 
and causes an imbalance between vasodilators (NO) 
and vasoconstrictors (endothelin-1) that impacts 
SVR[46]. Our data suggests that modulation of NO is 
linked to iNOS. Studies by others have reported that 
thalidomide does not change endothelin-1 levels in 
human endothelial cells[47]. While the vascular response 
to thalidomide was not the original focus of this study, 
we did observe that heart rate was not affected by 
thalidomide. This suggests changes in SVR, CVR or 
SV. TNFα has been shown to directly increase cardiac 
index and mean arterial pressure, systemic vascular 
resistance index, temperature, and heart rate[48,49]. 
However, because there appears to be no discernable 
increase in TNFα within the PVL murine model of PHT, 
other models are required to fully understand the 
connections amongst TNFα, thalidomide and PHT. 
In conclusion, although previous reports demonstrate 
the importance of TNFα in the development of PHT, 
TNFα does not appear to be important in the murine 
PVL model. This correlates with our previous study 
demonstrating that gene deletion of TNFα receptors 
does not ameliorate PHT in mice following PVL[50]. 
Consequently, the PVL model of PHT is not conducive 
to the study of TNFα in PHT. Despite this lack of TNFα 
involvement, thalidomide treatment demonstrated 
a temporary reduction in PHT via a NOS isoform 
independent mechanism, indicating a non-TNFα and 
non-NO mechanism for thalidomide in PHT. While 
this observation is interesting because thalidomide 
may be beneficial for the treatment of PHT associated 
variceal formation and bleeding, the use of thalidomide 
is cautioned since thalidomide is associated with 
thromboembolic events that would exacerbate PHT and 
enhance liver damage[51]. However, use of thalidomide 
analogs may demonstrate therapeutic benefit without 
vascular complications[52]. Further investigation is 
required to better understand the mechanism by 
which thalidomide reduces portal pressure with the 
anticipation that advances can be translated to clinical 
practice and improve outcomes for patients with liver 
disease and a high risk of developing PHT. We do not 
suggest by what mechanism thalidomide reduces 
mean arterial blood pressure because thalidomide 
is linked to many biological mechanisms, including 
vascular endothelial growth factor and thromboxane, 
both of which have been linked to PHT[53-55]. Moreover, 
thalidomide is known to modulate PHT via cannabinoid 
receptor-2 (CB2) expression and studies show that 
targeting CB2 receptor agonists ameliorate PHT in 
bile duct ligated rats and that thalidomide increases 
CB2 receptor expression and reduces cannabinoid 
receptor-1 expression[56,57]. 
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purpose of this study was to test this hypothesis using mice that have targeted 
gene deletions affecting NO biosynthesis. 
Research frontiers
There is a need to find alternative treatment paradigms for treating portal 
hypertension, including diagnosis, measurement and treatment. Thalidomide 
has been shown to reduce portal pressure and thalidomide derivatives are 
being explored. The hot spot is to better understand how these compounds 
work in order to facilitate translation in to the clinic. 
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The innovation of this research is the utilization of gene deleted mice and 
the microsurgery. In combination, this provides a cleaner understanding of 
the role of individual genes within disease pathology. The portal vein ligation 
model avoids the inflammatory and cytokine milieu associated with the carbon 
tetrachloride or bile duct ligation models of portal hypertension. 
Applications 
This study confirms that thalidomide does reduce portal hypertension but that 
this response is transient and last about 1 h. Moreover, the reduction is not 
linked to NO biosynthesis but via a nitric oxide synthase (NOS) independent 
reduction in mean systolic pressure. These results support the use of 
thalidomide or its derivatives and will direct further studies to investigate 
alternative targets other than NO. 
Terminology
Portal hypertension is driven by two main pathologies and both are related 
to NO. Reduced hepatic NO biosynthesis causes sinusoidal constriction that 
increases resistance to portal flow and increases portal pressure. In contrast, 
NO is increased within the systemic vasculature, resulting in increased cardiac 
output and increased portal venous flow that increase portal pressure. 
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The authors examined the hypothesis that thalidomide diminishes tumor 
necrosis factor alpha induction of NOS and the production of NO. They 
concluded that the transitory reduction in portal pressure was associated with 
an inducible NOS dependent increase in NO and a NOS isoform independent 
reduction in blood pressure.
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